The clinical effect of loratadine, a second generation antihistamine with weak sedation, was examined in 38 patients with asteatotic eczema, including xeroderma, who were not responding adequately to treatment with moisturizing agents. Patients achieving less than 50% improvement from baseline by the Visual Analogue Scale (VAS) of “daytime itching” and “nighttime itching” after one week of treatment with a moisturizing agent were considered to have inadequate response and received loratadine additionally. Of 66 patients examined, inadequate response was observed in 38 patients; 8 of these patients also received topical steroids at the physician's discretion. Anti-pruritic effect was examined based on the VAS score separately for the 30 patients with inadequate response and for the 8 who additionally received topical steroids. The VAS score for “daytime itching” of the 30 subjects not receiving a topical steroid was significantly reduced from 35.6±25.8 (mean±SD) before the addition of loratadine to 17.2±18.1, 15.7±20.1, 13.7±17.8, and 12.5±16.5 after 1, 2, 3, and 7 weeks, respectively. The VAS score for “nighttime itching” was also significantly reduced with the addition of loratadine from 45.0±24.2 to 24.3±18.3, 20.7±21.7, 19.2±19.7, and 15.1±16.3 after 1, 2, 3 and 7 weeks, respectively. The VAS score of the 8 patients likewise decreased over time, with the decrease being significant at all time points except for daytime itching after one week. In addition, the clinical efficacy of loratadine was evaluated in the 30 patients not receiving topical steroids, and marked or moderate efficacy was observed in 80% (24 patients) of the subjects. As an adverse reaction, mild sleepiness was observed in 2 patients (5.3%). These results suggested that loratadine, having weak sedation and confirmed antipruritic effect, is useful for the treatment of asteatotic eczema, including xeroderma.
View full abstract